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Biochemical and genetic characterization of Trypanosoma cruzi
N-myristoyltransferase
Adam J. ROBERTS*, Leah S. TORRIE*, Susan WYLLIE* and Alan H. FAIRLAMB*1
*Division of Biological Chemistry and Drug Discovery, College of Life Sciences, University of Dundee, Dundee DD1 5EH, U.K.
Co- and post-translational N-myristoylation is known to play a
role in the correct subcellular localization of specific proteins in
eukaryotes. The enzyme that catalyses this reaction, NMT (N-
myristoyltransferase), has been pharmacologically validated as a
drug target in the African trypanosome, Trypanosoma brucei. In
the present study, we evaluate NMT as a potential drug target in
Trypanosoma cruzi, the causative agent of Chagas’ disease, using
chemical and genetic approaches. Replacement of both allelic
copies of TcNMT (T. cruzi NMT) was only possible in the presence
of a constitutively expressed ectopic copy of the gene, indicating
that this gene is essential for survival of T. cruzi epimastigotes.
The pyrazole sulphonamide NMT inhibitor DDD85646 is 13–23-
fold less potent against recombinant TcNMT than TbNMT (T.
brucei NMT), with K i values of 12.7 and 22.8 nM respectively,
by scintillation proximity or coupled assay methods. DDD85646
also inhibits growth of T. cruzi epimastigotes (EC50 = 6.9 μM),
but is ∼1000-fold less potent than that reported for T. brucei. On-
target activity is demonstrated by shifts in cell potency in lines that
over- and under-express NMT and by inhibition of intracellular
N-myristoylation of several proteins in a dose-dependent manner.
Collectively, our findings suggest that N-myristoylation is an
essential and druggable target in T. cruzi.
Key words: Chagas’ disease, click chemistry, drug target,
N-myristoylation, Trypanosoma cruzi, validation.
INTRODUCTION
The protozoan parasite Trypanosoma cruzi is the causative agent
of Chagas’ disease, which is endemic in Latin American countries.
There are an estimated 8–10 million infected individuals
worldwide, with an annual death toll of ∼10000 per annum
[1–3]. Migration from endemic countries has also led to the
worldwide distribution of Chagas’ disease [1]. The acute stage
of this disease often has very mild and non-specific symptoms
that occur 4–8 weeks post-infection, resulting in only 1–2%
of all infected individuals being diagnosed in this stage [4].
Approximately 30% of infected individuals go on to develop the
chronic disease, most often characterized by heart abnormalities,
and to a lesser extent, mega-organ disease affecting the digestive
tract [2]. To date, benznidazole and nifurtimox are the only
approved drugs available for the treatment of Chagas’ disease.
Prolonged treatment with these nitroimidazoles during the acute
stage cures up to 70% of individuals; however, the efficacy
of these drugs significantly decreases in the chronic stage [5].
Both therapies have been associated with severe toxic side
effects that can lead to the interruption or discontinuation of
treatment in as many as 30% of cases [6,7]. At present, there
are two drugs being clinically assessed for the treatment of
asymptomatic chronic Chagas’ disease, posaconazole (Merck;
ClinicalTrials.gov Identifiers NCT01377480 and NCT01162967)
and E1224 (Eisai; ClinicalTrials.gov Identifier NCT01489228).
However, bearing in mind the high levels of drug candidate
attrition in the clinical trials process, there remains an urgent
need to identify new drug targets and better drugs to treat this
disease.
The enzyme NMT (N-myristoyltransferase; EC 2.3.1.97)
catalyses the co- and post-translational addition of myristic acid
(C14:0) on to the N-terminal glycine residue of specific proteins
[8,9]. This irreversible modification plays an important role in
the correct cellular localization and biological function of the
modified proteins. This enzyme has been extensively studied in
a number of organisms including the trypanosomatid parasites
Trypanosoma brucei and Leishmania major [10–15]. In these
parasitic organisms, NMT has been demonstrated to be essential
for viability either by classical gene knockout with episomal
rescue or by RNAi, indicating that the N-myristoylation of
certain proteins is a key biological process. Moreover, in the
African trypanosome, NMT is now pharmacologically validated
with compounds such as DDD85646 that specifically inhibit
the enzyme and are curative in the mouse model of stage one
African sleeping sickness [13]. Amino acid sequence comparisons
indicate that the T. cruzi enzyme is approximately 60% identical
to those of Leishmania spp. and various African trypanosomes.
Although metabolic labelling studies in the parasite have
confirmed that multiple proteins are N-myristoylated [16], T. cruzi
NMT has not been characterized biochemically or assessed for
essentiality or druggability. With this in mind, in our present
study, we utilize both genetic and chemical approaches to assess
the essentiality of the enzyme in T. cruzi.
MATERIALS AND METHODS
Parasite and mammalian cell culture
T. cruzi epimastigotes from the Silvio strain (MHOM/
BR/78/Silvio; clone X10/7) were grown at 28 ◦C in RTH/FBS
[RPMI 1640 medium supplemented with trypticase, haemin,
Hepes and 10% heat-inactivated FBS (PAA Laboratories; now
GE Healthcare)] [17]. {The Silvio strain, originally isolated
Abbreviations: CAP5.5, cytoskeleton-associated protein 5.5; DIG, digoxigenin; DKO, double knockout; DMEM, Dulbecco’s modified Eagle’s medium;
HYG, hygromycin phosphotransferase; NMT, N-myristoyltransferase; NMTOE, NMT overexpressor; PAC, puromycin N-acetyltransferase; RTH/FBS, RPMI
1640 medium supplemented with trypticase, haemin, Hepes and 10% heat-inactivated FBS; SKO, single knockout; TbNMT, Trypanosoma brucei NMT;
TCEP, tris-(2-carboxyethyl)phosphine; TcNMT, Trypanosoma cruzi NMT; TcTryR, Trypanosoma cruzi trypanothione reductase; WT, wild-type.
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Table 1 Primers used in the present study
Complementary sequences to ORFs are capitalized. Restriction sites are underlined.
Primer Sequence
TcNMT-pTREX_s 5′-gaattcATGGCAGAAGAGGGTTCAGGTTTACATCAG-3′
TcNMT-pTREX_as 5′-ctcgagCTATAGCATGAACAATCCCACGTCACTTGG-3′
TcNMT-pET15b-TEV_s 5′-catATGGCAGAAGAGGGTTCAGGTTTACATCAG-3′
TcNMT-pET15b-TEV_as 5′-ggatccCTATAGCATGAACAATCCCACGTCACTTGG-3′
5′-UTR-NotI _s 5′-ataagaatgcggccgcGTGATCTTCTCAACAACAAAAATGGATGA-3′
5′-UTRHindIII/PmeI_as 5′-gtttaaacttacggaccgtcaagcttTCCTTCAAAAGGCGATCAAGTCCA-
AAATTAC-3′
3′-UTR-PmeI/BamHI_s 5′-gacggtccgtaagtttaaacggatccGATGCGGGCGGAATTTAGGAGAGA-
AGT-3′
3′-UTR-NotI_as 5′-ataagtaagcggccgcCCGCATCCAGCAGATGGATTAATCACCGT-3′
from a 19-year-old male patient (Silvio B.S.) living in Para´,
Brazil [18], is also incorrectly referred to as the Sylvio strain
in the literature.} Clone Silvio X10/7A, used in subsequent
experiments, was generated by limiting dilution. Stationary-phase
epimastigote cultures containing metacyclic trypomastigotes
were used to infect Vero cells. Trypomastigotes were recovered
from Vero cell monolayers infected with Silvio X10/7A at 5–
6 days post-infection [19]. For infectivity studies, Vero cells
were infected with transgenic T. cruzi trypomastigotes using a
multiplicity of infection of 5:1. Free-swimming trypomastigotes
were washed off after 12 h and the infected cells were re-
plated into 384-well plates (Corning® CellBIND®). After 72 h
the cells were fixed in PBS containing 1% formaldehyde
before staining with 5 μg·ml− 1 Hoechst 33342 in PBS containing
0.01% Triton X-100. Plates were imaged using a high content
microscope (Operetta, PerkinElmer), and the images captured
were processed using an automated image analysis software
(Columbus, PerkinElmer) to determine the percentage of infected
cells and the mean number of parasites per infected Vero cell. Vero
cells (Cercopithecus aethiops kidney cells; ATCC® CCL-81TM)
were cultured in DMEM (Dulbecco’s modified Eagle’s medium;
Lonza) supplemented with 10% heat-inactivated FBS at 37 ◦C
with 5% CO2 [20].
Cloning, expression and purification of recombinant TcNMT (T.
cruzi NMT)
The NMT ORF was identified from the Silvio X10/1 genome by
BLAST, using the CL-Brenner sequence (TriTrypDB accession
number TcCLB.511283.90) as a search template [21]. Primers
designed against this sequence, TcNMT-pET15b-TEV_s and
TcNMT-pET15b-TEV_as (Table 1), were used to amplify
the NMT ORF from Silvio X10/7A genomic DNA using
Pfu DNA polymerase (Promega). The resulting PCR product
was cloned into Zero Blunt® TOPO® and sequenced. TcNMT was
excised from Zero Blunt® TOPO®-TcNMT by digestion with the
appropriate restriction enzymes and ligated directly into linearized
pET15b-TEV.
The resulting pET15b-TcNMT expression construct was
transformed into RosettaTM (DE3)pLysS competent cells and
recombinant expression was carried out in auto-induction media
[22] at 20 ◦C for 48 h with agitation at 200 rev./min. The cells
were harvested (20 min, 4 ◦C and 5020 g), resuspended in lysis
buffer {25 mM Tris, 500 mM NaCl, 25 mM imidazole, 1 mM
TCEP [tris-(2-carboxyethyl)phosphine]/HCl, pH 8.5, DNAse I
(Sigma) and cOmplete EDTA-free protease inhibitors (Roche)}
and lysed at 30000 psi (1 psi = 6.9 kPa) using a Constant Systems
cell disruptor. Soluble protein was recovered by centrifugation
(30 min, 4 ◦C and 40000 g) and filtered (0.2 μm Sartorius) before
loading on to a pre-equilibrated HisTrap HP 5 ml column (GE
Healthcare). The protein was eluted using a gradient of 25–
500 mM imidazole. Fractions containing NMT were identified
by SDS/PAGE (4–12% gel), pooled and dialysed into buffer
A (25 mM Tris, 25 mM NaCl and 1 mM TCEP, pH 8.5). The
dialysed protein was loaded on to a 5 ml HiTrap Q HP column (GE
Healthcare) and eluted with a gradient of NaCl (25–500 mM) in
buffer A. Pooled fractions containing NMT were further purified
by size exclusion on a Superdex 75 26/60 column equilibrated
in buffer B (25 mM Tris/HCl, 150 mM NaCl and 1 mM TCEP,
pH 8.5). The purity and mass of the recovered recombinant NMT
was assessed by SDS/PAGE and MALDI–TOF carried out by
the FingerPrints Proteomics service at the University of Dundee.
The oligomeric structure was characterized by size-exclusion
chromatography using a Superdex 200 300/10 GL column (GE
Healthcare) equilibrated with buffer B.
GENERATION OF KNOCKOUT, OVEREXPRESSION AND RECOVERY
CONSTRUCTS
The primers used to generate constructs for genetic manipulation
were designed using the TcNMT X10/1 and flanking sequences in
TriTrypDB as a template (Table 1). The accuracy of all assembled
constructs was verified by sequencing. NMT gene replacement
cassettes were generated by amplifying a region of DNA
encompassing 449 bp of the 5′-UTR, the ORF and 449 bp of
the 3′-UTR of TcNMT from genomic DNA with primers 5′-UTR-
NotI_s and 3′-UTR-NotI_as, using Pfu DNA polymerase. This
sequence was then used as a template for the amplification of the
individual regions used in the assembly of replacement cassettes
containing the selectable drug resistance genes PAC (puromycin
N-acetyltransferase) and HYG (hygromycin phosphotransferase),
exactly as described previously [23]. To generate a construct
for use as both a recovery and NMT-overexpressing vector in
knockout and WT (wild-type) parasites, NMT was amplified
from genomic DNA using the primers TcNMT-pTREX_s and
TcNMT-pTREX_as and cloned into the constitutive expression
vector pTREX [24] using the EcoRI and XhoI cloning sites.
Generation of transgenic T. cruzi cell lines
Transfections of T. cruzi epimastigotes were carried out using
an Amaxa NucleofectorTM electroporator, as described previously
[25]. A total of 5–10 μg of DNA was transfected into early-
to mid-log epimastigotes (1×107), suspended in Human T-cell
NucleofectorTM solution (100 μl; Lonza), using the program U-33.
At 24 h following transfection, 10 μg·ml− 1 puromycin (Sigma),
250 μg·ml− 1 G418 (Gibco®) or 500 μg·ml− 1 hygromycin
(Roche) was added to cultures of transgenic parasites. Following
drug selection, the parasites were cloned on to semi-solid agar
plates [1% Agar Noble (DifcoTM) and RTH/FBS] containing
20 μg·ml− 1 puromycin, 500 μg·ml− 1 G418 or 750 μg·ml− 1
hygromycin, as appropriate. After 2–3 weeks at 28 ◦C, colonies
were picked and grown in fresh RTH/FBS plus the appropriate
drug.
In vitro drug sensitivity assays
To examine the effects of test compounds on growth, triplicate
epimastigote cultures were seeded with 1×105 cells·ml− 1.
Parasites were grown in 10-ml cultures in the presence of
drug for 120 h. Cells were fixed in PBS (137 mM NaCl,
2.7 mM KCl, 10 mM Na2HPO4 and 1.8 mM KH2PO4) containing
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
permits unrestricted use, distribution and reproduction in any medium, provided the original work is properly cited.
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1% formaldehyde and manually counted using a Neubauer
haemocytometer. Data were processed using GraFit (version
5.0.4; Erithacus software) and fitted to a 2-parameter equation
(eqn 1) to obtain the effective EC50:
y = 100
1 +
(
[I]
EC50
)m (1)
In this equation, [I] represents inhibitor concentration and m is
the slope factor. The data are presented as the means +− S.D.
Quantification of cellular levels of NMT in lysates
Epimastigotes and trypomastigotes were harvested by centrifuga-
tion (15 min, 20 ◦C, 1620 and 2000 g respectively) and washed
twice in PBS. Amastigotes were purified from a mixed population
of trypomastigotes and amastigotes released from an infected Vero
cell monolayer [25a]. Briefly, parasites were collected by centri-
fugation (10 min, 20 ◦C, 4000 g) and the pellet incubated for 3 h at
37 ◦C overlaid with DMEM/FBS. Motile trypomastigotes released
into the supernatant were removed and the pellet was resuspended
in DMEM/FBS. This process was repeated twice to produce a
pure population of amastigotes (∼95%). Cells (5×107) were re-
suspended in Laemmli buffer (Bio-Rad Laboratories) and heated
at 95 ◦C for 10 min. The equivalent of 1×107 cells were separated
by SDS/PAGE on a 4–12%NuPAGE® gel. Cellular proteins were
transferred on to ProtranTM nitrocellulose membrane (Whatman)
by electrotransfer. Membranes were probed with primary rat
antisera generated against either TcNMT or TcTryR (T. cruzi
trypanothione reductase) [26] (both 1:500 dilution) before probing
with an HRP (horseradish peroxidase)-conjugated rabbit anti-rat
polyclonal secondary serum (1:10000; Dako). TcNMT-specific
polyclonal antiserum was raised against the recombinant His6–
TcNMT (CL-Brenner) in adult male Wistar rats, as described pre-
viously [27]. Immunization protocols were approved by the Uni-
versity Welfare and Ethical Use of Animals Committee and were
performed under the Animals (Scientific Procedures) Act 1986
in accordance with the European Communites Council Directive
(86/609/EEC). The blot was developed using ECL detection re-
agent kit (GE Healthcare) and exposed to Amersham HyperfilmTM
ECL (GE Healthcare). The developed film was scanned and the
protein bands were quantified by densitometry with ImageJ (NIH).
Southern blot analyses of transgenic T. cruzi cell lines
The ORFs of TcNMT , PAC and HYG were amplified by PCR
(using the primers described previously for the cloning of
TcNMT and knockout constructs) using the PCR DIG Probe
Synthesis Kit (Roche). The resulting DIG (digoxigenin)-labelled
products were used as probes. Samples of genomic DNA
(5 μg) from WT and transgenic cell lines were digested with
appropriate restriction endonucleases, the digestion products
were then separated on a 0.8% agarose gel and transferred to a
positively charged nylon membrane (Roche). The membrane was
hybridized overnight in DIG Easy Hyb solution (Roche) at 42 ◦C
with the DIG-labelled probes (2 μl of PCR product). Following
hybridization, membranes were washed twice in low stringency
conditions (25 ◦C, 5 min, 2× SSC buffer with 0.1% SDS) and
twice in high stringency conditions (68 ◦C, 15 min, 0.5× SSC
with 0.1% SDS), where 1× SSC comprises 150 mM NaCl and
50 mM sodium acetate, pH 7.0. The bound probe was detected
using the DIG immunological detection kit (Roche) as per the
manufacturer’s instructions.
Detection of cellular N-myristoylation
Mid-log epimastigotes were harvested by centrifugation and
resuspended at 1×107 cells·ml− 1 in fresh RTH/FBS. Various
concentrations of DDD85646 (0, 12.5, 25, 50 and 100 μM) were
added to epimastigote cultures 30 min before the addition of
50 μM Click-IT® myristic acid (Invitrogen) and cultures were
then incubated for a further 5 h. Following incubation, cells
were washed (three times in PBS), the resulting cell pellet was
resuspended in lysis buffer (150 μl, 50 mM Tris/HCl, pH 7.4,
150 mM NaCl, 1% sodium deoxycholate, 0.1% SDS, 1%Triton
X-100 and a cOmplete mini EDTA-free protease inhibitor cocktail
tablet) and incubated on ice for 1 h. Lysates were clarified by
centrifugation (10 min, 4 ◦C and 14000 g) and quantified with
the Bio-Rad Laboratories protein assay using BSA as a standard.
IRDye® 800CW alkyne (LI-COR Biosciences) was ligated to
Click-IT® myristic acid using the Click-IT® protein reaction
buffer set (Invitrogen) and methanol/chloroform precipitated,
according to the manufacturer’s instructions. Treated lysates
(12 μg) were separated by SDS/PAGE, fixed in 10% acetic acid
and 40% methanol. The fixed gel was washed in 0.2 M NaOH
for 1 h before washing briefly in H2O and imaged by in-gel
fluorescence using an Odyssey Sa infrared imaging system (LI-
COR Biosciences). Quantification of band intensities was carried
out using Image Studio Lite (version 3.1; LI-COR Biosciences).
Cells not labelled with azidomyristate were used for a background
fluorescence measurement to correct the values obtained for N-
myristoylated proteins. Intensities are expressed as a percentage
of the no drug control.
Metabolic labelling
Parasites were incubated in a methionine-free RTH/FBS medium
that was supplemented with 10 μCi·ml− 1 L-[35S]methionine
(PerkinElmer). After incubating with the same concentrations of
inhibitor and azidomyristate as mentioned above, the parasites
were washed three times in PBS and boiled in Laemmli buffer
for 10 min. A total of 5×106 parasites per lane were separated
by SDS/PAGE and stained with Coomassie Blue. The gel was
incubated in EN3HANCETM solution (PerkinElmer) as per the
manufacturer’s protocol and then gel dried. The gel was exposed
to BioMax MS film (Kodak) using a BioMax TranScreen LE
(Kodak) for 8 h.
Kinetic analysis of TcNMT
Kinetic analysis [Km(app) and kcat values] of TcNMT activity
was performed at 30 ◦C using a previously published coupled-
enzyme spectrophotometric assay monitoring the increase in
absorbance at 340 nm [28]. Each 0.25 ml assay contained
50 mM Tris, 0.5 mM EDTA, 0.5 mM EGTA, 1.25 mM DTT,
0.1% Triton X-100, 40 mM pyruvic acid, 0.125 units·ml− 1
pyruvate dehydrogenase, 0.2 mM thiamine pyrophosphate,
40 μM myristoyl-CoA and 2.5 mM NAD+ , adjusted to pH 7.4
with HCl. Km(app) values were determined for a biotinylated
peptide substrate derived from amino acids 2–15 of T. brucei
[13] and T. cruzi CAP5.5 (cytoskeleton-associated protein
5.5) (TcCAP5.5 GCCASKEKQPRPGAK[biotin], TbCAP5.5
GCGGSKVKPQPPQAK[biotin], custom synthesized by Pep-
ceuticals) and for myristoyl-CoA (Sigma). The IC50 value of
DDD85646 for recombinant NMT was determined using this
coupled-enzyme assay. The K i(app) was determined by fitting the
resulting data to the Morrison equation (eqn 2), allowing the true
K i value to be determined using eqn (3). In a comparative study,
the kinetic parameters of TcNMT (5 nM per assay) were also
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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Figure 1 Genotypic analysis of WT, SKO and rescue DKO cell lines
Southern blot analysis of AgeI and XmnI digested genomic DNA (∼5 μg) from WT T. cruzi (clone Silvio X10/7A) cells (lane 1), NMT SKO (PAC) cells (lane 2), NMT SKO (HYG) cells (lane
3), NMT SKO (PAC) cells constitutively expressing NMT (lane 4), NMT DKO (PAC and HYG) cells constitutively expressing NMT (lane 5) and ‘pseudo’ NMT DKO (PAC and HYG) cells (lanes
6–8). The maps show the predicted fragment sizes for the WT and for correct replacement with drug resistance markers. Southern blots were probed with (A) NMT ORF, (B) HYG and (C)
PAC.
determined using a scintillation proximity method, as described
previously [13,29]. The myristoyl-CoA Km(app) was determined
using CAP5.5 at 600 μM or 50 μM in the coupled-enzyme and
scintillation proximity assays respectively. The CAP5.5 Km(app)
values were determined using either 40 μM or 125 nM in the
coupled-enzyme or scintillation proximity assays.
vi
v0
=
([E]T − [I]T−K i(app))+
√([E]T − [I]T −K i(app))2 +4 [E]T [I]T
2 [E]T
(2)
K i = K i(app)(
1 + [S]
Km
) (3)
RESULTS
Generation of an NMT ‘rescued’ DKO (double knockout) cell line
Restriction enzyme digestion and Southern blotting analysis of
T. cruzi X10/7A DNA indicated that NMT is a single copy gene
per haploid genome (results not shown). DNA sequencing of
PCR products gave identical amino acid sequences apart from a
serine or proline residue at position 150, probably due to allelic
variation. The essentiality of NMT in T. cruzi epimastigotes
was then assessed using a classical two-step gene replacement
strategy where NMT is sequentially replaced by homologous
recombination with drug resistance genes and drug selection
(Figure 1). The first gene copy of NMT could be successfully
replaced with either hygromycin (HYG) or puromycin (PAC)
resistance genes resulting in two independent SKO (single
knockout) cell lines (Figures 1B, lane 3, and 1C, lane 2). Loss of
a single allelic copy of NMT did not markedly alter the growth
rate of SKO parasites. Several attempts were made to directly
replace the remaining allelic copy of NMT in the SKO-PAC
clone with HYG. In two out of three attempts, epimastigotes
that were resistant to both hygromycin and puromycin were
recovered following transfection. On the remaining occasion, no
live parasites were recovered. Southern blot analysis of genomic
DNA isolated from clones of putative DKO parasites revealed that
in all cases an endogenous copy of NMT was retained (Figure 1A,
lanes 6–8) along with a copy of PAC at the NMT locus
(Figure 1C, lanes 6–8). Moreover, probing these blots with
the HYG probe showed that this drug resistance gene had not
integrated into the T. cruzi genome (Figure 1B, lanes 6 and 7).
PCR of these failed DKO attempts suggest that the HYG resistance
gene is present as a multicopy episome. In another of these clones,
HYG was not only present as an episomal copy, but also integrated
at the NMT locus with retention of a copy of NMT (Figures 1A
and 1B, lane 8). We have not investigated whether the latter is due
to amplification of all or part of the NMT chromosome resulting
in aneuploidy, as has been observed in Leishmania spp. [30].
Owing to the failure to directly produce NMT DKO
epimastigotes, a ‘rescued’ DKO cell line was generated. First,
a constitutively expressed ectopic copy of NMT was targeted to
the ribosomal locus of SKO-PAC parasites (Figure 1A, lane 4).
Only then was it possible to replace the last allelic copy of NMT
in cells, due to the presence of an episomal copy of the gene
(Figure 1A, lane 5). These findings provide strong evidence that
NMT is essential for growth and survival of T. cruzi epimastigotes
in vitro.
Infectivity of transgenic parasites
The ability to infect Vero cells was quantified to determine
whether the presence of an ectopic copy or the deletion of a
single allele of TcNMT affected the virulence of these parasites.
Representative images of uninfected and infected Vero cells are
shown (Figures 2A and 2B respectively). The deletion of a single
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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Figure 2 Infectivity of transgenic T. cruzi parasites
(A) Uninfected Vero cells stained with Hoechst 33342. (B) Vero cells infected with WT T. cruzi. (C) The percentage of Vero cells infected with WT, SKO-PAC, SKO-HYG and NMTOE transgenic
parasites. Differences in the percentage of WT compared with SKO-PAC and SKO-HYG parasites were confirmed to be statistically significant (*P < 0.01) using an unpaired Student’s t test. (D)
The mean number of amastigotes per infected Vero cell of WT, SKO-PAC, SKO-HYG or NMTOE parasites. Differences in the percentage of WT compared with SKO-PAC and NMTOE parasites were
confirmed to be statistically significant (P < 0.01) using an unpaired Student’s t test (*P < 0.05, ***P < 0.001). A total of 24 measurements were made for each parameter. Data are shown as
means +− S.E.M. NS, not significant.
allele in both cases led to a very minor increase in the percentage
of infected cells compared with the WT, whereas the presence
of an ectopic copy [NMTOE (NMT overexpressor)] had no effect
(Figure 2C). Absolute numbers of parasites per infected Vero
cell were also monitored (Figure 2D). Vero cells infected with
SKO-PAC and NMTOE parasites were found to have marginally
reduced parasite loads compared with WT. Despite the statistical
differences between some, but not all, cell lines, these changes
are not relevant biologically as all lines showed similar infection
profiles.
Expression of NMT in T. cruzi life-cycle stages
For technical reasons, it is not possible to genetically validate
NMT in the clinically relevant non-dividing trypomastigote stage
and intracellular amastigote stage by gene knockout. However,
we were able to confirm that NMT is expressed in all stages of the
parasite’s life cycle by probing an immunoblot of crude lysates
with a TcNMT-specific antiserum (Figure 3). Single bands of
approximately 53 kDa, close to the predicted molecular mass
of NMT (51.4 kDa), were detected in all three lysates indicating
that NMT is expressed at all stages of the parasite life cycle. The
cellular concentration of NMT in each of these parasite stages
was determined by densitometry and previously published cell
volumes [31]. Using this information, NMT concentrations in
each stage of the parasite were estimated to be within a 2-fold
range; 1.2, 2.1 and 2.5 μM in the epimastigote, trypomastigote
and amastigote respectively.
Sensitivity to DDD85646 shifts with NMT expression levels
The pyrazole sulphonamide DDD85646 has been shown to
specifically inhibit TbNMT (T. brucei NMT) in vitro and cure
the stage 1 murine model of human African trypanosomiasis
[13]. To establish whether this inhibitor can also chemically
target the T. cruzi enzyme, the comparative sensitivity of WT
epimastigotes and transgenic cell lines with different levels
of NMT to DDD85646 was determined. In the first instance,
altered levels of NMT expression in transgenic parasites were
confirmed by Western blot, using TcTryR as a loading control
(Figure 4A). Cellular levels of NMT were analysed in WT
parasites, the SKO cell line generated previously (SKO-PAC)
and in an NMT overexpressing cell line (NMTOE) which was
generated by transfecting pTREX-NMT into WT epimastigotes.
Densitometry revealed that SKO-PAC parasites contained NMT
protein levels ∼2.5-fold lower than the WT, with levels in the
NMTOE epimastigotes ∼7.6-fold higher. Varying the cellular
levels of NMT within these parasites was found to markedly
alter their sensitivity to DDD85646 with WT, SKO-PAC and
NMTOE cell lines having EC50 values of 6.3, 2.9 and 78.6 μM
respectively (Figure 4B). The clear relationship observed between
the levels of NMT expression and the sensitivity of the
parasites for this compound confirms that TcNMT is specifically
targeted by DDD85646 and thus may be druggable in T.
cruzi. There was no selectivity between the amastigote and
Vero cells with DDD85646 [EC50 values of 8.7 +− 0.8 μM and
6.7 +− 1 μM (n = 4) respectively]. The actual EC50 value for the
amastigote may be higher as the parasite cannot replicate in
the absence of the host cell.
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Figure 3 Cellular levels of NMT in T. cruzi life-cycle stages
Immunoblots of whole cell extracts (equivalent of 1×107 parasites in each lane) from T. cruzi
epimastigotes, trypomastigotes and amastigotes were probed with TcNMT-specific polyclonal
antiserum. Known amounts of purified recombinant TcNMT were loaded as standards for the
quantification of the cellular levels of NMT. The difference in size between recombinant and
cellular NMT is due to the His6-tag on the recombinant protein.
DDD85646-mediated inhibition of N-myristoylation
To confirm DDD85646-mediated inhibition of N-myristoylation
within T. cruzi epimastigotes, parasites were pre-treated
with a range of inhibitor concentrations for 30 min. N-
azidomyristoylated proteins were detected by in-gel fluorescence.
It is evident that there is some non-specific interaction of the
dye with an unlabelled 49 kDa protein (Figure 4A, upper panel,
lane 1). Labelling parasites with this myristic acid analogue led to
the NMT-mediated incorporation of azidomyristate into multiple
T. cruzi proteins (Figure 4A, upper panel, lane 2). In parasites
treated with DDD85646, we observe that six bands were depleted
in a dose-dependent manner which was confirmed by quantifying
the fluorescent intensities of the bands (Figures 5A, upper panel,
and 5B). The most prominent effect was observed for a ∼20 kDa
band, where the N-myristoylation of this protein decreased to
40% of the untreated control, at the lowest inhibitor concentration
tested (∼2×EC50). The remaining bands are insensitive over 5.5 h
exposure to DDD85646 at the range of concentrations tested.
Labelling parasites with L-[35S]methionine revealed no inhibition
of nascent protein synthesis (Figure 5A, lower panel), indicating
that the observed inhibition of N-myristoylation is due to the
direct inhibition of cellular NMT. These data further demonstrate
the on-target activity of the inhibitor DDD85646 in T. cruzi.
Kinetic characterization of recombinant TcNMT
In order to facilitate kinetic studies of TcNMT, the recombinant
enzyme was expressed and purified to homogeneity. Escherichia
coli RosettaTM (DE3)pLysS cells transformed with pET15b-
TEV-TcNMT produced soluble and active protein. TcNMT was
purified following three chromatographic steps to obtain a yield of
2.5 mg·l− 1 (Figure 6A). Analysis of the recombinant protein by
size-exclusion chromatography revealed that His6–NMT elutes
primarily as a monomer at ∼47.4 kDa, close to the predicted
molecular mass of 53.7 kDa (Figure 6B). This was confirmed
by MS to be 53.7 kDa for the tagged recombinant protein by
MALDI–TOF analysis.
Multiple assays already exist for the kinetic characterization
of NMTs using HPLC, ELISA, scintillation proximity assay or
spectrophotometric methodologies [9,29,32,33]. In the present
study, we have compared the scintillation proximity assay with a
modified version of a coupled-enzyme spectrophotometric assay
[28]. The basic kinetic parameters of TcNMT [Km(app) and kcat]
were measured in these assays for CAP5.5, a protein known to
be N-myristoylated in T. brucei [34] (Table 2). Synthetic peptides
based on the amino acids 2–15 of CAP5.5 from both T. brucei and
T. cruzi were used as substrates in these assays. In the coupled-
enzyme assay, the Km value determined for TbCAP5.5 was
∼21-fold higher than observed for TcCAP5.5, but the catalytic
Figure 4 Effects of NMT modulation on DDD85646 susceptibility
(A) Immunoblots of whole cell extracts (equivalent of 1×107 parasites in each lane) of WT, NMT SKO and NMT-overexpressing epimastigotes were probed with TcNMT-specific polyclonal antiserum.
A duplicate blot was probed with antiserum against TcTryR to act as a loading control. (B) EC50 values were determined for DDD85646 against WT (closed circles), SKO (PAC) (open circles)
and NMT-overexpressing parasites (open squares). EC50 values of 6.3 +− 0.1, 2.9 +− 0.04 and 78.6 +− 4.6 μM were determined for DDD85646 against WT, SKO and NMT-overexpressing cell lines
respectively. Data are shown as means +− S.D. for triplicate cultures.
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Figure 5 DDD85646-mediated inhibition of cellular N-myristoylation
Mid-log epimastigotes were pre-treated with varying concentrations of DDD85646 (0–15×EC50) for 5.5 h. (A) N-myristoylated proteins were detected by click chemistry ligation of an alkyne
fluorescent dye on to azidomyristate-labelled proteins (upper panel) and protein synthesis assessed by L-[35S]methionine labelling of parasites (lower panel). Circles highlight bands that are sensitive
to NMT inhibition that were quantified in (B). (B) Reduction in fluorescence intensity as a function of DDD85646 concentration.
Figure 6 Purification of recombinant TcNMT
(A) SDS/PAGE of purification of recombinant TcNMT. Lane 1, insoluble fraction of RosettaTM 2 (DE3)pLysS [pET15b-TcNMT], induced; lane 2, soluble fraction of RosettaTM 2 (DE3)pLysS
[pET15b-TcNMT], induced; lane 3, pooled fractions from Ni2 + -affinity chromatography; lane 4, pooled fractions from anion exchange chromatography (Q Sepharose); and lane 5, pooled fractions
from size-exclusion chromatography. (B) Gel filtration profile of the His6-tagged TcNMT. The inset shows a plot of V e/V 0 against the log molecular mass (Mw) of a standard protein mixture (open
circles), where V e is the elution volume and V 0 is the void volume of the column. The closed circle represents the elution volume of NMT.
c© 2014 The Author(s) The author(s) has paid for this article to be freely available under the terms of the Creative Commons Attribution Licence (CC-BY) (http://creativecommons.org/licenses/by/3.0/) which
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Table 2 Kinetic characterization of recombinant TcNMT
Data for the TbNMT column are taken from [13,29]. n.d., not determined.
Parameter
Coupled-enzyme
assay
Scintillation
proximity assay TbNMT
K m(app) (μM)
Myristoyl-CoA 6.2 +− 0.6 5.3 +− 1.0 1.78
TbCAP5.5 250 +− 28 2.2 +− 0.2 11.3
TcCAP5.5 12.1 +− 1 1.6 +− 0.15 –
k cat (s− 1)
Myristoyl-CoA 0.34 +− 0.01 n.d. –
TbCAP5.5 2.11 +− 0.05 n.d. –
TcCAP5.5 0.15 +− 0.003 n.d. –
k cat/K m (M− 1·s− 1)
Myristoyl-CoA 54.8×103 – –
TbCAP5.5 8.44×103 – –
TcCAP5.5 12.4×103 – –
Inhibition by DDD85646
K i(app) (nM) 41.2 +− 5.4* 16.6 +− 4.4† 1.44
K i (nM) 22.8 12.7 1.04
*Determined using 150 nM TcNMT, 200 μM TbCAP5.5 and 40 μM myristoyl-CoA.
†Determined using 5 nM TcNMT. 0.5 μM TcCAP5.5 and 0.125 μM myristoyl-CoA.
efficiencies (kcat/Km) of both substrates were found to be similar.
For reasons of cost, it was not possible to determine the Km values
in the presence of saturating concentrations of myristoyl-CoA
using the scintillation proximity assay, allowing only a Km(app)
value to be determined for each peptide. Using this assay, the
Km(app) values for the peptide substrates were very similar at 1.6 and
2.2 μM. In the coupled-enzyme assay (in the presence of 600 μM
TbCAP5.5), the Km(app) value of the myristoyl-CoA substrate was
6.2 +− 0.6 μM, which is not statistically different from the value of
5.3 +− 1.0 μM determined in the scintillation proximity assay (in
the presence of 50 μM TcCAP5.5) (P = 0.252) Student’s t test.
Inhibition of recombinant TcNMT by DDD85646
DDD85646 is a potent inhibitor of T. brucei recombinant NMT
[K i(app) = 1.44 nM] and inhibits the growth of T. brucei blood-
stream parasites in vitro at similar concentrations (EC50 = 2.1 nM)
[13]. In comparison, we noted that DDD85646 was far less potent
against T. cruzi epimastigotes (EC50 = 6.3 μM) (Figure 4B).
Since we have demonstrated that DDD85646 specifically inhibits
TcNMT in vitro, the drop-off in cellular potency could be in
part explained by differences in active site architecture leading
to a decreased affinity for the inhibitor. To test this hypothesis,
the K i value of DDD85646 was determined against the T. cruzi
recombinant enzyme using both the scintillation proximity assay
and coupled assay (Table 2). Under both sets of assay conditions,
the K i of DDD85646 was calculated to be ∼12.7–22.8 nM, which
is 13–23-fold less potent than against the T. brucei enzyme. In
contrast with T. brucei, there is a drop-off in culture potency of
two orders of magnitude between target and cell activity.
DISCUSSION
The paucity of validated drug targets in T. cruzi has severely
hampered the search for better and more effective treatments for
Chagas’ disease. Previous studies have shown that the enzyme
encoded by the NMT gene is essential for the survival of
many eukaryotic organisms [10,12,35,36], including the related
trypanosomatids L. major and T. brucei [12]. Metabolic labelling
studies in T. cruzi have already revealed that N-myristoylation
occurs in this parasite and plays a role in the correct cellular
localization of the flagellar calcium-binding protein [16,37]. The
genetic studies investigated in the present study indicate that
TcNMT is an essential gene in the epimastigote stage of the
parasite, since we were unable to directly replace both endogenous
copies of NMT , except in the presence of an ectopic copy
of the gene. Although we have carried out genetic validation of
TcNMT in the epimastigote stage of the parasite, there is clear
evidence to show that the enzyme is also present in the clinically
relevant stages. Therefore it is likely that N-myristoylation is
also an essential cellular process during the trypomastigote and
amastigote stages of development.
The comparative profiling of NMT substrate specificities from
multiple organisms has revealed that there are subtle species-
specific differences in the N-myristoylation motif of protein
substrates recognized by each homologue. These differences have
already been exploited to generate inhibitors which are up to 560-
fold more potent against a fungal enzyme than the human enzyme
[38]. Several high-throughput inhibitor-screening programmes
have been carried out in recent years with the aim of identifying
both potent and selective inhibitors of NMT from the target
species [13,39,40]. One such campaign led to the development
of DDD85646, a highly potent inhibitor of T. brucei and human
NMT [13]. Despite selectivity at the target level being only 2-
fold, this increases to 200-fold at the cellular level. The reason
for biological selectivity is not fully understood and may involve
pleiotropic biological effects. Depletion of NMT by RNAi in
this parasite leads to impairment of the endocytic pathway [41],
a process that is known to involve the N-myristoylated protein
TbARF1 (T. brucei ARF1) [42]. Endocytosis and exocytosis
in T. brucei occurs exclusively from a specialized invagination
of the plasma membrane known as the flagellar pocket. Owing to
the high endocytic/exocytic rate, the entire plasma membrane of
the parasite is turned over in approximately 12 min, considerably
faster than that of mammalian macrophages or fibroblasts [43].
Treatment of T. brucei with DDD85646 causes a massively
enlarged flagellar pocket or ‘big eye’ phenotype [13], as found
by RNAi knockdown of either clathrin heavy chain [44] or
ARF1 [42], suggesting that endocytosis, but not exocytosis, is
inhibited. Curiously, knockdown of NMT itself does not produce
this phenotype, despite inhibiting endocytosis [41]. Nonetheless,
the marked sensitivity of the T. brucei bloodstream parasite to
NMT inhibition can be attributed at least partly to the high rate
of endocytosis/exocytosis and the consequent high turnover of
plasma membrane in the flagellar pocket [13].
Although DDD85646 is a potent inhibitor of the T. cruzi
enzyme, there is a considerable drop off in potency against the
intact parasite (epimastigote or amastigote), in marked contrast
with T. brucei where DDD85646 is equipotent against both
the enzyme and the parasite [13]. The reason for this is not
clear, but could be due to differences in the rate of plasma
membrane turnover, differences in other essential biological
functions requiring N-myristoylation or due to differences in
cellular pharmacokinetics of drug uptake or efflux. The kinetics
of endocytosis has not been studied in T. cruzi. However, it is
worth noting that endocytosis in T. cruzi epimastigotes occurs
principally via another membrane invagination adjacent to the
flagellar pocket (the cytostome) and not the flagellar pocket itself
[45].
Our studies clearly demonstrate that NMT is an essential
and druggable enzyme in T. cruzi, thus it is entirely plausible
that parasite-specific N-myristoylated proteins may also be
potential drug targets in their own right. To date, only
two T. cruzi proteins (flagellar calcium-binding protein and
phosphoinositide-specific phospholipase C) have been defin-
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itively confirmed to be N-myristoylated [16,37], although
two studies have predicted many proteins may undergo this
modification [46,47]. Although our studies identify at least
ten distinct bands, treatment of epimastigotes with DDD85646
was only able to specifically block the N-myristoylation of
six in vitro under the experimental conditions used in the
present study. Although it is possible to theoretically predict N-
myristoylated proteins from any completed genome [46,48], these
bioinformatics and predictive approaches have several drawbacks.
Most notably, using known N-myristoylated motifs from various
organisms to inform our identification of N-myristoylated proteins
in T. cruzi may well lead to difficulties, since previous studies
have shown a degree of variability in this motif across different
organisms [49–51]. With this in mind, work is underway to
identify directly the N-myristoylated proteins comprising the T.
cruzi N-myristoylome using a click chemistry approach.
In conclusion, we have demonstrated that NMT from T. cruzi
is both an essential and druggable target. However, discovery of
more potent and selective inhibitors will be required to achieve a
suitable therapeutic window for the treatment of Chagas’ disease.
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